Investor Presentation H1 2023

146 Investor presentation First six months of 2023 Resource allocation in Novo Nordisk is guided by investing in future growth while delivering attractive shareholder returns Corporate strategy guides resource allocation Expected primary sales growth drivers towards 2030 Diabetes care Strengthen leadership by offering innovative medicines and driving patient outcomes Rare disease Secure a leading position by leveraging full portfolio and expanding into adjacent areas Novo Nordisk Way Driving change to defeat diabetes and other serious chronic diseases Sustainable business Ge PR Obesity care Strengthen treatment options through market development and by offering innovative medicines and driving patient outcomes Other serious Waves of growth chronic diseases Establish presence by building competitive pipeline and scientific leadership GLP-1 Diabetes Focus on driving sustained sales growth • Commercial investments in growth markets and products • R&D investments in future growth assets R&D: Research and Development; OSCD: Other serious chronic diseases Obesity care OSCD Novo NordiskⓇ ILLUSTRATIVE Research technology Rare disease platforms 2020 2025 2030

View entire presentation